Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients

INTRODUCTION: Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects. METHODS: The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative...

Descripción completa

Detalles Bibliográficos
Autores principales: Tylicki, Leszek, Biedunkiewicz, Bogdan, Ślizień, Zuzanna, Muchlado, Marta, Dębska-Ślizień, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266872/
https://www.ncbi.nlm.nih.gov/pubmed/35832697
http://dx.doi.org/10.5114/aoms/150000
_version_ 1784743576405540864
author Tylicki, Leszek
Biedunkiewicz, Bogdan
Ślizień, Zuzanna
Muchlado, Marta
Dębska-Ślizień, Alicja
author_facet Tylicki, Leszek
Biedunkiewicz, Bogdan
Ślizień, Zuzanna
Muchlado, Marta
Dębska-Ślizień, Alicja
author_sort Tylicki, Leszek
collection PubMed
description INTRODUCTION: Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects. METHODS: The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative kidney transplant recipients (KTRs) after three doses of the BNT162b2 mRNA vaccine. Twelve seronegative KTRs received a mRNA-1273 booster 5 months after the third dose of BNT162b2. RESULTS: A total of 5 out of 12 patients (41.7%) seroconverted, with a mean titer of 353 BAU/ml. CONCLUSIONS: The administration of a heterologous mRNA vaccine as a booster may be an effective alternative for achieving post-vaccination immunity in seronegative KTRs.
format Online
Article
Text
id pubmed-9266872
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-92668722022-07-12 Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients Tylicki, Leszek Biedunkiewicz, Bogdan Ślizień, Zuzanna Muchlado, Marta Dębska-Ślizień, Alicja Arch Med Sci Research Letter INTRODUCTION: Three-dose mRNA vaccination against COVID-19 is unable to elicit a sufficient immune response in immunocompromised subjects. METHODS: The aim of the study was to conduct a retrospective evaluation of the efficacy of a heterologous mRNA booster with mRNA-1273 in constantly seronegative kidney transplant recipients (KTRs) after three doses of the BNT162b2 mRNA vaccine. Twelve seronegative KTRs received a mRNA-1273 booster 5 months after the third dose of BNT162b2. RESULTS: A total of 5 out of 12 patients (41.7%) seroconverted, with a mean titer of 353 BAU/ml. CONCLUSIONS: The administration of a heterologous mRNA vaccine as a booster may be an effective alternative for achieving post-vaccination immunity in seronegative KTRs. Termedia Publishing House 2022-06-23 /pmc/articles/PMC9266872/ /pubmed/35832697 http://dx.doi.org/10.5114/aoms/150000 Text en Copyright: © 2022 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Research Letter
Tylicki, Leszek
Biedunkiewicz, Bogdan
Ślizień, Zuzanna
Muchlado, Marta
Dębska-Ślizień, Alicja
Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
title Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
title_full Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
title_fullStr Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
title_full_unstemmed Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
title_short Heterologous high dose SARS-CoV-2 mRNA vaccine booster may improve immune response in seronegative kidney transplant recipients
title_sort heterologous high dose sars-cov-2 mrna vaccine booster may improve immune response in seronegative kidney transplant recipients
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266872/
https://www.ncbi.nlm.nih.gov/pubmed/35832697
http://dx.doi.org/10.5114/aoms/150000
work_keys_str_mv AT tylickileszek heterologoushighdosesarscov2mrnavaccineboostermayimproveimmuneresponseinseronegativekidneytransplantrecipients
AT biedunkiewiczbogdan heterologoushighdosesarscov2mrnavaccineboostermayimproveimmuneresponseinseronegativekidneytransplantrecipients
AT slizienzuzanna heterologoushighdosesarscov2mrnavaccineboostermayimproveimmuneresponseinseronegativekidneytransplantrecipients
AT muchladomarta heterologoushighdosesarscov2mrnavaccineboostermayimproveimmuneresponseinseronegativekidneytransplantrecipients
AT debskaslizienalicja heterologoushighdosesarscov2mrnavaccineboostermayimproveimmuneresponseinseronegativekidneytransplantrecipients

Ejemplares similares